Inbiomotion

The company develops the MAF Test®, a diagnostic biomarker designed to improve patient selection for adjuvant bisphosphonate treatment in early breast cancer. The test identifies patients with normal MAF gene expression who are likely to benefit from the therapy while excluding those with over-expression who may face a higher risk of metastasis or harm. This precision medicine tool targets oncologists and pathologists to help personalize treatment plans and prevent metastatic spread.